The stage of pancreatic cancer at diagnosis has a significant impact on survival. Pancreatic cancer diagnosed at its earliest stage (IA) improves the expected 5-year survival rate to approximately 80%.
With the disease projected to become the second leading cause of cancer death by 2030, earlier detection is key to improving outcomes. The Avantect test gives clinicians a powerful new tool to act before symptoms appear.
Certain clinical and inherited factors are recognized as purple flags associated with elevated pancreatic cancer risk. The Avantect Pancreatic Cancer Test is designed for individuals with one or more of these risk factors:
Of pancreatic cancer
BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, EPCAM, CDKN2A, PRSS1, SPINK1, or STK11
Newly diagnosed in adults age ≥50
Other pancreatic cancer risk factors may exist, including high BMI/physical inactivity, smoking, diabetes mellitus, chronic pancreatitis, and pancreatic cysts. These factors are provided for education only and should be interpreted within the Avantect Pancreatic Cancer Test's intended use and limitations.
Epigenetic changes are present in the earlier stages of pancreatic cancer. Chemical modifications of DNA such as 5-hydroxymethylcytosine (5hmC) have now been identified as powerful biomarkers for pancreatic cancer.
The Avantect Pancreatic Cancer Test is a multiomics assay that integrates epigenomic 5hmC patterns, genomic and genotyping information from cfDNA, and glycan biomarker measurements within an optimized machine learning algorithm to produce a single blood-based result intended to detect pancreatic cancer signals at early stages of disease.
Clinically validated in a study of pancreatic cancer patients (n=259) and non-cancer subjects (n=1,186).
Developed on over 5,000 training and validation samples.
The Avantect test is easily incorporated into clinical management protocols for patients at high risk for pancreatic cancer. A simple blood draw can provide life-changing information.
Order online or through your clinician. A collection kit ships directly to your care facility or your door.
A simple blood draw. No special preparation required. Ship using the pre-paid materials included in the kit.
Test results delivered to your ordering provider within 14 days. Clear Detected / Not Detected format with next-step guidance.
The Avantect Pancreatic Cancer Test evaluates the presence or absence of a pancreatic cancer–associated signal. Each result helps guide discussions between patients and their healthcare providers.
The test identified an abnormal signal associated with a malignancy of the pancreas. Your healthcare provider will determine the appropriate next steps, which may include imaging or additional diagnostic testing to clarify this result.
A cancer signal was not found with this test. This does not exclude the presence of pancreatic cancer. If signs or symptoms appear and are suggestive of cancer, please consult your healthcare provider.
The Avantect Pancreatic Cancer Test is the only multiomics liquid biopsy clinically validated to detect pancreatic cancer with this level of accuracy — from a simple blood draw.
Easily incorporated into clinical management protocols for patients you know to be at high risk. A result in 14 days. Life-changing information that can guide the next steps in care.
Complete this form and a specialist will reach out within 1–2 business days.
Prefer to use our main contact page? Visit humanlongevity.com/contact →
The Avantect Pancreatic Cancer Test is an early detection test. The test does not establish a diagnosis of pancreatic cancer, and results should be considered in the context of other clinical criteria. A definitive diagnosis of cancer is rendered by clinical providers through a combined use of diagnostic testing, imaging, biopsy, and pathological findings. Not all pancreatic cancers will be detected. Some patients with pancreatic cancer may have a "Signal not detected" result. Some patients without pancreatic cancer may have a "Signal detected" result. False-negative and false-positive results are possible.
The test was developed in the Human Longevity, Inc. CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).